Bionomics Limited (NASDAQ:BNOX – Get Free Report) saw a significant decrease in short interest in September. As of September 30th, there was short interest totalling 73,000 shares, a decrease of 39.4% from the September 15th total of 120,400 shares. Based on an average daily trading volume, of 964,700 shares, the days-to-cover ratio is currently 0.1 days.
Bionomics Trading Up 3.6 %
Shares of BNOX stock opened at $0.28 on Monday. The stock’s fifty day simple moving average is $0.56 and its 200-day simple moving average is $0.76. Bionomics has a 1-year low of $0.25 and a 1-year high of $4.73.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Bionomics in a research note on Thursday, August 1st.
Hedge Funds Weigh In On Bionomics
A hedge fund recently bought a new stake in Bionomics stock. Armistice Capital LLC purchased a new position in Bionomics Limited (NASDAQ:BNOX – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned about 15.03% of Bionomics at the end of the most recent quarter. Institutional investors own 15.90% of the company’s stock.
About Bionomics
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.
Further Reading
- Five stocks we like better than Bionomics
- What is a Secondary Public Offering? What Investors Need to Know
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- How to Use Stock Screeners to Find Stocks
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.
